Small molecule · Inhibitor of Niemann-Pick C1-Like 1 protein (NPC1L1) and HMG-CoA reductase (HMGCR) · developed by Organon
Ezetimibe/simvastatin is a combination of ezetimibe, which binds the sterol transporter NPC1L1 at the small intestinal brush border to inhibit cholesterol absorption, and simvastatin, which after conversion to its active beta-hydroxyacid form competitively inhibits HMG-CoA reductase in cholesterol synthesis. It is studied in hypercholesterolemia and atherosclerosis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Nov 25, 2025). Read the full label for the exact wording, limitations and safety information.
AtherosclerosisHypercholesterolemia
Updated Oct 25, 2026. Something wrong or missing? Report it on the OGN page.
See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OGN catalysts and pipeline →